Success Metrics

Completion Rate

0%(0/1)

Active Trials

3(60%)

Terminated

1(20%)

Phase Distribution

Ph not_applicable

20%

Ph phase_3

40%

Ph phase_2

40%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 2Efficacy & side effects

2(40.0%)

Phase 3Large-scale testing

2(40.0%)

N/ANon-phased studies

1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(4)

Terminated(1)

Detailed Status

Recruiting2

Not yet recruiting1

Terminated1

Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

0.0%

Most Advanced

Phase 3

Trials by Phase

Phase 22 (40.0%)

Phase 32 (40.0%)

N/A1 (20.0%)

Trials by Status

not_yet_recruiting120%

terminated120%

active_not_recruiting120%

recruiting240%

Recent Activity

3 active trials

Showing 5 of 5

active_not_recruitingphase_3

Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)

NCT06726265

recruitingphase_2

Personalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer

NCT07023484

recruitingphase_2

Personalised Timing of Interval Debulking Surgery in Advanced Ovarian Cancer

NCT07022535

not_yet_recruitingnot_applicable

A Multi-cohort Study of Efbemalenograstim Alfa Injection for Preventing ANC Reduction in Solid Tumor Patients Post Immune-chemotherapy.

NCT06649448

terminatedphase_3

A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)

NCT00300885

Clinical Trials (5)

Showing 5 of 5 trials

NCT06726265Phase 3

Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)

Active Not Recruiting

NCT07023484Phase 2

Personalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer

Recruiting

NCT07022535Phase 2

Personalised Timing of Interval Debulking Surgery in Advanced Ovarian Cancer

Recruiting

NCT06649448Not Applicable

A Multi-cohort Study of Efbemalenograstim Alfa Injection for Preventing ANC Reduction in Solid Tumor Patients Post Immune-chemotherapy.

Not Yet Recruiting

NCT00300885Phase 3

A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)

Terminated

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5